17.53
3.97%
+0.67
Biolife Solutions Inc stock is currently priced at $17.53, with a 24-hour trading volume of 392.30K.
It has seen a +3.97% increased in the last 24 hours and a -3.15% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $16.69 pivot point. If it approaches the $17.71 resistance level, significant changes may occur.
Previous Close:
$16.86
Open:
$16.95
24h Volume:
392.30K
Market Cap:
$794.11M
Revenue:
$143.27M
Net Income/Loss:
$-66.43M
P/E Ratio:
-9.0829
EPS:
-1.93
Net Cash Flow:
$-18.88M
1W Performance:
+10.53%
1M Performance:
-3.15%
6M Performance:
+85.31%
1Y Performance:
-2.50%
Biolife Solutions Inc Stock (BLFS) Company Profile
Name
Biolife Solutions Inc
Sector
Industry
Phone
425-402-1400
Address
3303 Monte Villa Parkway, Suite 310, Bothell, WA
Biolife Solutions Inc Stock (BLFS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-11-23 | Initiated | Craig Hallum | Buy |
Apr-25-22 | Upgrade | Oppenheimer | Perform → Outperform |
Oct-19-21 | Initiated | B. Riley Securities | Buy |
Oct-15-21 | Resumed | Cowen | Outperform |
May-14-21 | Downgrade | The Benchmark Company | Buy → Hold |
Mar-23-21 | Upgrade | The Benchmark Company | Hold → Buy |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
Sep-22-20 | Downgrade | Oppenheimer | Outperform → Perform |
Sep-18-20 | Initiated | Cowen | Outperform |
Aug-11-20 | Downgrade | The Benchmark Company | Buy → Hold |
Jul-08-20 | Reiterated | Maxim Group | Buy |
Feb-24-20 | Initiated | Lake Street | Buy |
Feb-19-20 | Initiated | The Benchmark Company | Buy |
Feb-06-20 | Resumed | B. Riley FBR | Buy |
Jan-08-20 | Initiated | Stephens | Overweight |
Nov-21-19 | Initiated | Oppenheimer | Outperform |
Jul-22-19 | Initiated | H.C. Wainwright | Buy |
Nov-10-17 | Reiterated | Maxim Group | Buy |
Sep-19-17 | Reiterated | Maxim Group | Buy |
Jul-05-17 | Upgrade | Janney | Neutral → Buy |
Mar-10-17 | Reiterated | Maxim Group | Buy |
Jan-19-17 | Initiated | Maxim Group | Buy |
View All
Biolife Solutions Inc Stock (BLFS) Latest News
Biolife Solutions Inc Stock (BLFS) Financials Data
Biolife Solutions Inc (BLFS) Revenue 2024
BLFS reported a revenue (TTM) of $143.27 million for the quarter ending December 31, 2023, a -11.43% decline year-over-year.
Biolife Solutions Inc (BLFS) Net Income 2024
BLFS net income (TTM) was -$66.43 million for the quarter ending December 31, 2023, a +52.49% increase year-over-year.
Biolife Solutions Inc (BLFS) Cash Flow 2024
BLFS recorded a free cash flow (TTM) of -$18.88 million for the quarter ending December 31, 2023, a -0.03% decrease year-over-year.
Biolife Solutions Inc (BLFS) Earnings per Share 2024
BLFS earnings per share (TTM) was -$1.52 for the quarter ending December 31, 2023, a +53.80% growth year-over-year.
About Biolife Solutions Inc
BioLife Solutions, Inc. develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death. The company offers HypoThermosol FRS, a hypothermic storage and shipping media product to mitigate temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications; and CryoStor cryopreservation freeze media products to mitigate temperature-induced molecular cell stress responses during freezing and thawing. It also provides BloodStor freeze media products, such as BloodStor 55-5 and BloodStor 100 for cryopreservation of stem and other cells isolated from umbilical cord and peripheral blood, and bone marrow; and cell thawing media, which offers Dextran and saline for washing cryopreserved cells and tissues to dilute or remove cryoprotectants. In addition, the company provides custom product formulation and packaging services; and contract aseptic manufacturing formulation, filling, and finishing services for liquid media products. It markets its products to the regenerative medicine, bio-banking, and drug discovery markets, including hospital-based stem cell transplant centers, pharmaceutical companies, cord blood and adult stem cell banks, and hair transplant centers, as well as suppliers of cells to the drug discovery, toxicology testing, and diagnostic markets. The company markets and sells its products directly using its sales force, as well as through biolifesolutions.com; and through various regional distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Cap:
|
Volume (24h):